Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: A brief review;A szorongásos betegségek kezelésének farmakogenetikai aspektusai a szerotonerg rendszeren túl: Rövid összefoglalás

Neuropsychopharmacologia Hungarica

Volumn 14, Issue 4, 2012, Pages 221-229

  Faludi, Gabor ^a   Gonda, Xenia ^a   Bagdy, Gyorgy ^a   Dome, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anxiety disorders; Anxiolytics; Benzodiazepines; Panic disorder; Pharmacogenetics; PTSD; Selective serotonin reuptake inhibitors; Treatment response

Indexed keywords

ACYLTRANSFERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUSPIRONE; CATECHOL METHYLTRANSFERASE; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; DULOXETINE; EXCITATORY AMINO ACID TRANSPORTER 3; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYZINE; PAROXETINE; PLACEBO; PREGABALIN; PSYCHOTROPIC AGENT; RIMONABANT; VENLAFAXINE;

ANXIETY DISORDER; COGNITIVE THERAPY; DEPRESSION; DNA POLYMORPHISM; DRUG METABOLISM; FUNCTIONAL NEUROIMAGING; GENERALIZED ANXIETY DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAMILTON ANXIETY SCALE; HUMAN; MAJOR DEPRESSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PANIC; PHARMACOGENETICS; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXCITATORY AMINO ACID TRANSPORTER 3; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MONOAMINE OXIDASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS;

EID: 84874064589     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: 10.5706/nph201212002     Document Type: Review

References (78)

1. Akimova, E., Lanzenberger, R., Kasper, S. (2009) The serotonin- 1A receptor in anxiety disorders. Biol Psychiatry, 66: 627-635.
2. Andrisano, C., Chiesa, A., Serretti, A. (2012) Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol, 9: 84-101.
3. Bagdy, G. (2012) Génjeink és a lelki egészség. A stressz hatásának és a depresszió genomikájának összefüggései és tanulságai. Magyar Tudomány, 173: 660-672.
4. Bagdy, G., Graf, M., Anheuer, Z. E., Modos, E. A., Kantor, S. (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol, 4: 399-408.
5. Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Allgulander, C., Ayuso-Gutierrez, J., Baldwin, D. S., Buenvicius, R., Cassano, G., Fineberg, N., Gabriels, L., Hindmarch, I., Kaiya, H., Klein, D. F., Lader, M., Lecrubier, Y., Lepine, J. P., Liebowitz, M. R., Lopez-Ibor, J. J., Marazziti, D., Miguel, E. C., Oh, K. S., Preter, M., Rupprecht, R., Sato, M., Starcevic, V., Stein, D. J., van Ameringen, M., Vega, J. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry, 9: 248-312.
6. Bockting, C. L., Mocking, R. J., Lok, A., Koeter, M. W., Schene, A. H. (in press) Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy?Mol Psychiatry.
7. Brandl, E. J., Muller, D. J., Richter, M. A. (2012) Pharmacogenetics of obsessive-compulsive disorders. Pharmacogenomics, 13: 71-81.
8. Bryant, R. A., Felmingham, K. L., Falconer, E. M., Pe Benito, L., Dobson-Stone, C., Pierce, K. D., Schofield, P. R. (2010) Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry, 67: 1217-1219.
9. Chang, S. C., Koenen, K. C., Galea, S., Aiello, A. E., Soliven, R., Wildman, D. E., Uddin, M. (2012) Molecular variation at the SLC6A3 locus predicts lifetime risk of PTSD in the Detroit Neighborhood Health Study. PLoS One, 7: e39184.
10. Chen, Z. Y., Jing, D., Bath, K. G., Ieraci, A., Khan, T., Siao, C. J., Herrera, D. G., Toth, M., Yang, C., McEwen, B. S., Hempstead, B. L., Lee, F. S. (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science, 314: 140-143.
11. Corregiari, F. M., Bernik, M., Cordeiro, Q., Vallada, H. (2012) Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Clinics (Sao Paulo), 67: 335-340.
12. Diemer, J., Vennewald, N., Domschke, K., Zwanzger, P. (2010) Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety. Eur Arch Psychiatry Clin Neurosci, 260: S127-131.
13. Dome, P., Lazary, J., Kalapos, M. P., Rihmer, Z. (2010) Smoking, nicotine and neuropsychiatric disorders. Neurosci Biobehav Rev, 34: 295-342.
14. Domschke, K., Deckert, J. (in press) Genetics Of Anxiety Disorders Status Quo And Quo Vadis. Curr Pharm Des.
15. Domschke, K., Lawford, B., Laje, G., Berger, K., Young, R., Morris, P., Deckert, J., Arolt, V., McMahon, F. J., Baune, B. T. (2010) Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol, 13: 93-101.
16. Durant, C., Christmas, D., Nutt, D. (2010) The pharmacology of anxiety. Curr Top Behav Neurosci, 2: 303-330.
17. Eley, T. C., Hudson, J. L., Creswell, C., Tropeano, M., Lester, K. J., Cooper, P., Farmer, A., Lewis, C. M., Lyneham, H. J., Rapee, R. M., Uher, R., Zavos, H. M., Collier, D. A. (2012) Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry, 17: 236-237.
18. Fernandez, S. P., Gaspar, P. (2012) Investigating anxiety and depressive-like phenotypes in genetic mouse models of serotonin depletion. Neuropharmacology, 62: 144-154.
19. Fukasawa, T., Suzuki, A., Otani, K. (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther, 32: 333-341.
20. Fullana, M. A., Alonso, P., Gratacos, M., Jaurrieta, N., Jimenez-Murcia, S., Segalas, C., Real, E., Estivill, X., Menchon, J. M. (2012) Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder. Eur Psychiatry, 27: 386-390.
21. Hedman, E., Andersson, E., Ljotsson, B., Andersson, G., Schalling, M., Lindefors, N., Ruck, C. (2012) Clinical and genetic outcome determinants of internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta Psychiatr Scand, 126: 126-136.
22. Hong, C. J., Liou, Y. J., Tsai, S. J. (2011) Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res Bull, 86: 287-297.
23. Ipser, J. C., Stein, D. J. (2012) Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol, 15: 825-840.
24. Ishiguro, S., Watanabe, T., Ueda, M., Saeki, Y., Hayashi, Y., Akiyama, K., Saito, A., Kato, K., Inoue, Y., Shimoda, K. (2011) Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol, 67: 1213-1221.
25. Kessler, R. C., Ruscio, A. M., Shear, K., Wittchen, H. U. (2010) Epidemiology of anxiety disorders. Curr Top Behav Neurosci, 2: 21-35.
26. Kim, W., Choi, Y. H., Yoon, K. S., Cho, D. Y., Pae, C. U., Woo, J. M. (2006) Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry, 30: 1413-1418.
27. Kirilly, E., Gonda, X., Bagdy, G. (2012) CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf), 205: 41-60.
28. Kirilly, E., Hunyady, L., Bagdy, G. (in press) Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J Neural Transm.
29. Klauke, B., Deckert, J., Zwanzger, P., Baumann, C., Arolt, V., Pauli, P., Reif, A., Domschke, K. (in press) Neuropeptide S receptor gene (NPSR) and life events: G x E effects on anxiety sensitivity and its subdimensions. World J Biol Psychiatry.
30. Kolassa, I. T., Kolassa, S., Ertl, V., Papassotiropoulos, A., De Quervain, D. J. (2010) The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-omethyltransferase Val(158)Met polymorphism. Biol Psychiatry, 67: 304-308.
31. Lawford, B. R., Mc, D. Y. R., Noble, E. P., Kann, B., Arnold, L., Rowell, J., Ritchie, T. L. (2003) D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. Eur Neuropsychopharmacol, 13: 313-320.
32. Lazary, J., Juhasz, G., Hunyady, L., Bagdy, G. (2011) Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci, 32: 270-280.
33. Lazary, J., Lazary, A., Gonda, X., Benko, A., Molnar, E., Hunyady, L., Juhasz, G., Bagdy, G. (2009) Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am J Med Genet B Neuropsychiatr Genet, 150B: 1118-1127.
34. Lesch, K. P., Zeng, Y., Reif, A., Gutknecht, L. (2003) Anxietyrelated traits in mice with modified genes of the serotonergic pathway. Eur J Pharmacol, 480: 185-204.
35. Lesser, I. M., Lydiard, R. B., Antal, E., Rubin, R. T., Ballenger, J. C., DuPont, R. (1992) Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry, 149: 1556-1562.
36. Lester, K. J., Hudson, J. L., Tropeano, M., Creswell, C., Collier, D. A., Farmer, A., Lyneham, H. J., Rapee, R. M., Eley, T. C. (2012) Neurotrophic gene polymorphisms and response to psychological therapy. Transl Psychiatry, 2: e108.
37. Lohoff, F. W., Aquino, T. D., Narasimhan, S., Multani, P. K., Etemad, B., Rickels, K. (in press a) Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J.
38. Lohoff, F. W., Narasimhan, S., Rickels, K. (in press b) Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J.
39. Lonsdorf, T. B., Ruck, C., Bergstrom, J., Andersson, G., Ohman, A., Lindefors, N., Schalling, M. (2010) The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry, 10: 99.
40. Lowry, C. A., Hale, M. W., Evans, A. K., Heerkens, J., Staub, D. R., Gasser, P. J., Shekhar, A. (2008) Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci, 1148: 86-94.
41. Marazziti, D., Carlini, M., Dell'Osso, L. (2012) Treatment strategies of obsessive-compulsive disorder and panic disorder/ agoraphobia. Curr Top Med Chem, 12: 238-253.
42. Maron, E., Hettema, J. M., Shlik, J. (2010) Advances in molecular genetics of panic disorder. Mol Psychiatry, 15: 681-701.
43. Maron, E., Nutt, D. J., Kuikka, J., Tiihonen, J. (2010) Dopamine transporter binding in females with panic disorder may vary with clinical status. J Psychiatr Res, 44: 56-59.
44. Maron, E., Shlik, J. (2006) Serotonin function in panic disorder: important, but why? Neuropsychopharmacology, 31: 1-11.
45. Mekli, K., Payton, A., Miyajima, F., Platt, H., Thomas, E., Downey, D., Lloyd-Williams, K., Chase, D., Toth, Z. G., Elliott, R., Ollier, W. E., Anderson, I. M., Deakin, J. F., Bagdy, G., Juhasz, G. (2011) The HTR1A and HTR1B receptor genes influence stress-related information processing. Eur Neuropsychopharmacol, 21: 129-139.
46. Merikangas, K. R., Kalaydjian, A. E. Epidemiology of anxiety disorders. In: Sadock, B. J., Sadock, V. A., Ruiz, P., Kaplan, H. I. (Eds), Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2009, pp. 1856-1864.
47. Miguita, K., Cordeiro, Q., Shavitt, R. G., Miguel, E. C., Vallada, H. (2011) Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq Neuropsiquiatr, 69: 283-287.
48. Muller, D. J., Brandl, E. J., Hwang, R., Tiwari, A. K., Sturgess, J. E., Zai, C. C., Lieberman, J. A., Kennedy, J. L., Richter, M. A. (2012) The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarkers, 16: 897-903.
49. Narasimhan, S., Aquino, T. D., Hodge, R., Rickels, K., Lohoff, F. W. (2011) Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett, 503: 200-202.
50. Narasimhan, S., Aquino, T. D., Multani, P. K., Rickels, K., Lohoff, F. W. (2012) Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res, 198: 112-115.
51. Narasimhan, S., Lohoff, F. W. (2012) Pharmacogenetics of anti- depressant drugs: current clinical practice and future directions. Pharmacogenomics, 13: 441-464.
52. Paine, M. F., Criss, A. B., Watkins, P. B. (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos, 32: 1146-1153.
53. Perlis, R. H., Fijal, B., Dharia, S., Houston, J. P. (in press) Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J.
54. Perna, G., Favaron, E., Di Bella, D., Bussi, R., Bellodi, L. (2005) Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology, 30: 2230-2235.
55. Ravindran, L. N., Stein, M. B. (2010) The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry, 71: 839-854.
56. Real, E., Gratacos, M., Labad, J., Alonso, P., Escaramis, G., Segalas, C., Subira, M., Lopez-Sola, C., Estivill, X., Menchon, J. M. (in press) Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder. Pharmacogenomics J.
57. Real, E., Gratacòs, M., Soria, V., Escaramís, G., Alonso, P., Segalàs, C., Bayés, M., de Cid, R., Menchón, J. M., Estivill, X. (2009) A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol Psychiatry, 66: 674-680.
58. Reinhold, J. A., Mandos, L. A., Rickels, K., Lohoff, F. W. (2011) Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother, 12: 2457-2467.
59. Rowe, D. C., Stever, C., Gard, J. M., Cleveland, H. H., Sanders, M. L., Abramowitz, A., Kozol, S. T., Mohr, J. H., Sherman, S. L., Waldman, I. D. (1998) The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Genet, 28: 215-225.
60. Samochowiec, J., Hajduk, A., Samochowiec, A., Horodnicki, J., Stepien, G., Grzywacz, A., Kucharska-Mazur, J. (2004) Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res, 128: 21-26.
61. Schosser, A., Kasper, S. (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol, 24: 277-288.
62. Soliman, F., Glatt, C. E., Bath, K. G., Levita, L., Jones, R. M., Pattwell, S. S., Jing, D., Tottenham, N., Amso, D., Somerville, L. H., Voss, H. U., Glover, G., Ballon, D. J., Liston, C., Teslovich, T., Van Kempen, T., Lee, F. S., Casey, B. J. (2010) A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science, 327: 863-866.
63. Stingl, J. C., Brockmoller, J., Viviani, R. (in press) Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry.
64. Tadic, A., Rujescu, D., Szegedi, A., Giegling, I., Singer, P., Moller, H. J., Dahmen, N. (2003) Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am J Med Genet B Neuropsychiatr Genet, 117B: 1-6.
65. Taylor, S. (in press) Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol Psychiatry.
66. Tiwari, A. K., Souza, R. P., Muller, D. J. (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm, 116: 667-677.
67. Turu, G., Varnai, P., Gyombolai, P., Szidonya, L., Offertaler, L., Bagdy, G., Kunos, G., Hunyady, L. (2009) Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J Biol Chem, 284: 16914-16921.
68. Van Ameringen, M., Mancini, C., Patterson, B., Simpson, W. (2009) Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci, 46: 53-61.
69. Van Nieuwerburgh, F. C., Denys, D. A., Westenberg, H. G., Deforce, D. L. (2009) Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract, 13: 345-348.
70. Vulink, N. C. C., Westenberg, H. G. M., van Nieuwerburgh, F., Deforce, D., Fluitman, S. B. A. H. A., Meinardi, J. S. C., Denys, D. (2012) Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Int J Psychiatry Clin Pract. 16: 277-283.
71. Warwick, J. M., Carey, P. D., Cassimjee, N., Lochner, C., Hemmings, S., Moolman-Smook, H., Beetge, E., Dupont, P., Stein, D. J. (2012) Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metabolic Brain Disease, 27: 151-158.
72. Weizman, S., Gonda, X., Dome, P., Faludi, G. (2012) Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung, 14: 87-101.
73. Woo, J. M., Yoon, K. S., Choi, Y. H., Oh, K. S., Lee, Y. S., Yu, B. H. (2004) The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res, 38: 365-370.
74. Wu, G., Feder, A., Wegener, G., Bailey, C., Saxena, S., Charney, D., Mathe, A. A. (2011) Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opinion on Therapeutic Targets, 15: 1317-1331.
75. Wu, M., Hanna, G. L., Rosenberg, D. R., Arnold, P. D. (2012) The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacology Biochemistry and Behavior, 100: 726-735.
76. Yevtushenko, O. O., Oros, M. M., Reynolds, G. P. (2010) Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord, 123: 308-311.
77. Yevtushenko, O. O., Reynolds, G. P. (2010) Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action. Handbook of Behavioral Neuroscience, 21: 791-806.
78. Zhang, L., Liu, X., Li, T., Yang, Y., Hu, X., Collier, D. (2004) [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 21: 479-481.